Alembic Pharmaceuticals announced that the USFDA has conducted an inspection at Alembic Pharmaceuticals Formulation Facility located at Panelav from March 12, 2018 to March 20, 2018.

This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with 3 observations. 

The stock had outperformed the market over the past one month till Mar. 20, 2018, rising 3.10% compared with the Sensex's 2.10% decline.  It outperformed the market in past one quarter, gaining 10.11% as against 2.31% fall in the Sensex.

Shares of the company gained Rs 17.8, or 3.34%, to trade at  Rs 551.50.  The total volume of shares traded  was  7,651 at the BSE (9.24 a.m., Wednesday).